pegfilgrastim
Sign in to saveAlso known as N-(3-Hydroxypropyl)Methionylcolony-stimulating Factor (human), 1-Ether with .Alpha.-Methyl-.Omega.-Hydroxypoly(Oxyethylene), Pluripoietin, G-CSF, Granulocyte colony-stimulating factor precursor
Pegfilgrastim, sold under the brand name Neulasta among others, is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (GCSF) analog filgrastim. It serves to stimulate the production of white blood cells (neutrophils). Pegfilgrastim was developed by Amgen.
Research
1,251 papers- Pegfilgrastim.Drugs · 2002
- Pegfilgrastim-jmdb/MYL-1401H: A Pegfilgrastim Biosimilar.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2019
- Pegfilgrastim.Expert opinion on biological therapy · 2002
- Two decades of pegfilgrastim: what have we learned? Where do we go from here?Current medical research and opinion · 2023
- Pharmacokinetics of pegfilgrastim.Pharmacotherapy · 2003
via PubMed
~3 min read
Encyclopedic overview
4 sectionsContents
- Medical uses
- Society and culture
- Legal status
- References
Pegfilgrastim, sold under the brand name Neulasta among others, is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (GCSF) analog filgrastim. It serves to stimulate the production of white blood cells (neutrophils). Pegfilgrastim was developed by Amgen.
Pegfilgrastim treatment can be used to stimulate bone marrow to produce more neutrophils to fight infection in patients undergoing chemotherapy.
Excerpted from Wikipedia’s “pegfilgrastim” article, available under the CC BY-SA 4.0 licence.
Available in 14 languages
- Español
- Français
- Deutsch
- 中文
- العربية
- Bahasa Indonesia
- Hebrew
- Odia
- Serbian
- Serbian (Latin)
- Tiếng Việt
- Ukrainian
- فارسی
via Wikidata sitelinks · CC0